Replies to post #282216 on NorthWest Biotherapeutics Inc (NWBO)

[meirluc]

Then why didn't nwbo announce data lock at the 4/18 annual meeting?

They did not announce data lock on 4/18 because IMHO they wanted to incorporate all data concerned with the IDH1 mutation into the results of the trial. Consequently, data lock became dependent on completion of the identification of all tumors which carried the IDH1 mutation.

One can argue that the identification of this mutation was not part of the original protocol. However, LP & Co. concluded very late during this trial that this information is very important.

Therefore I am now of the opinion that LP postponed TLD by two months so as to integrate the mutation data into the trial and perhaps use it in subsequent trials.

The excuse that unresolved queries were responsible for the two months delay seems to me to be a smokescreen and a cover story to defend NWBO from the following obvious question: Why did NWBO not complete the mutation work much earlier during this trial?

[Sojourner55]

It's more likely the intent was to announce data lock at ASM on April 18 and that gives 6 weeks for TLD just in time for ASCO, IMO.